Morepen Laboratories Ltd is engaged in the business of manufacturing, producing, developing and marketing a wide range of Active Pharmaceutical Ingredients (APIs), branded and generic formulations and also the Home Health products. Presenting below are its Q1 FY26 earnings results.
Q1 FY26 Earnings Results
-
Total Income: ₹425 crores, a slight increase of 0.5% QoQ (Q4 FY25: ₹427.32 crores), but down 6.5% YoY (Q1 FY25: ₹458.64 crores).
-
Profit Before Tax (PBT): ₹15.52 crores, down 63.2% QoQ (Q4 FY25: ₹42.20 crores) and down 67.8% YoY (Q1 FY25: ₹48.17 crores).
-
Profit After Tax (PAT): ₹10.75 crores, down 62.0% QoQ (Q4 FY25: ₹28.28 crores) and down 69.4% YoY (Q1 FY25: ₹36.17 crores).
-
Earnings Per Share (EPS): ₹0.20, down 60% QoQ and 71.8% YoY.
-
Total Expenses: ₹414.14 crores, up 7.5% QoQ and 0.7% YoY.
-
Cost Details: Material consumption rose 1.14% YoY; employee expenses up 15.18% YoY; finance costs jumped 250.43% YoY; selling and distribution expenses increased 2.74% YoY.
-
Operational Segments: Morepen is involved in APIs, branded generics, medical devices, and consumer wellness products in domestic and international markets.
Key Management Commentary & Strategic Highlights
-
Management noted a challenging quarter driven by higher expenses and inflationary pressures impacting profitability despite steady revenue.
-
The company is focused on expanding medical devices segment, which grew 13% YoY in revenue, and boosting exports notably to Europe and Asia regions.
-
Investments in production capabilities are ongoing to meet increased market demand for glucometers and other devices.
-
Management aims to sustain growth through innovation, operational efficiency, and diversification of product offerings.
Q4 FY25 Earnings Results
-
Total Income: ₹466 crores.
-
PAT: ₹20 crores.
-
EPS: ₹0.37.
To view the company’s previous earnings and latest concall transcripts, click here to visit the Alphastreet India news channel.